Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Dr. Wang on the Benefit of BTK Inhibitors in MCL

January 6th 2020

Michael Wang, MD, discusses the benefit of BTK inhibitors in mantle cell lymphoma.

Dr. Andreadis on Treatment Approaches in Relapsed MCL

January 4th 2020

Charalambos (Babis) Andreadis, MD, MSCE, discusses the need to identify an optimal standard of care in patients with relapsed/refractory mantle cell lymphoma.

Wang Highlights Encouraging CAR T-Cell Activity in MCL

December 23rd 2019

Michael Wang, MD, discusses the ZUMA-2 trial and the potential impact of CAR T-cell therapy on the treatment paradigm in mantle cell lymphoma.

Maintenance Rituximab After R-CHOP Shows Continued Benefit in Older Patients With MCL

December 23rd 2019

Induction therapy with R-CHOP followed by maintenance rituximab continued to show improvements in survival and responses compared with R-CHOP and interferon-alpha maintenance in older patients with mantle cell lymphoma.

FDA Approval Sought for KTE-X19 in Relapsed/Refractory Mantle Cell Lymphoma

December 13th 2019

A biologics license application has been submitted to the FDA for the investigational CAR T-cell therapy KTE-X19 as a treatment for adult patients with relapsed/refractory mantle cell lymphoma.

Dr. Rule on Long-Term Follow-Up of Ibrutinib Monotherapy in Relapsed/Refractory MCL

December 11th 2019

Simon Rule, MD, professor of hematology, University of Plymouth, discusses long-term follow-up data from a pooled analysis of ibrutinib (Imbruvica) monotherapy in patients with relapsed/refractory mantle cell lymphoma (MCL).

KTE-X19 Shows High CR Rates for MCL, FDA Submission Planned

December 10th 2019

Treatment with the anti-CD19 CAR T-cell therapy KTE-X19 elicited a complete remission rate of 67% and an objective response rate of 93% for patients with relapsed/refractory mantle cell lymphoma.

Ibrutinib May Thwart PFS Decline in R/R Mantle Cell Lymphoma

December 9th 2019

In patients with relapsed mantle cell lymphoma, treatment with ibrutinib might mitigate a historical trend toward decreased progression-free survival with succeeding lines of therapy.

Dr. Rule on Potential for CAR T-Cell Therapy in MCL

December 7th 2019

Simon Rule, MD, discusses the potential for CAR T-cell therapy in treating patients with mantle cell lymphoma.

Dr. Gerson on Updates in Relapsed/Refractory MCL

December 6th 2019

James N. Gerson, MD, discusses recent updates in relapsed/refractory mantle cell lymphoma.

New BTK Agents and Combinations Are on the Horizon for B-cell Malignancies

December 5th 2019

During a recent OncLive Peer Exchange, a panel of leukemia and lymphoma experts discussed emerging BTK inhibitors.

Dr. Goy on Treating Older Patients With MCL

December 5th 2019

Andre Goy, MD, MS, discusses treatment approaches for older patients with mantle cell lymphoma.

Dr. Rule on the FDA Approval of Zanubrutinib in MCL

November 15th 2019

Simon Rule, MD, PhD, professor of hematology, Plymouth University Medical School, United Kingdom, discusses the FDA approval of zanubrutinib (Brukinsa) in mantle cell lymphoma (MCL).

FDA Approves Zanubrutinib for Relapsed/Refractory MCL

November 15th 2019

The FDA has granted an accelerated approval to zanubrutinib capsules for the treatment of adult patients with mantle cell lymphoma who have received ≥1 prior therapy.

Dr. Rule on the Future Treatment Paradigm in MCL

November 13th 2019

Simon Rule, MD, PhD, discusses what the treatment landscape of mantle cell lymphoma may look like in the next decade.

Cirmtuzumab/Ibrutinib Study Expands to Include Patients With MCL

November 8th 2019

The phase I/II CIRLL study, which is evaluating the combination of the monoclonal antibody cirmtuzumab (UC-961) plus ibrutinib has opened an expansion cohort to include patients with mantle cell lymphoma.

Expert Shares Insight on Precision Medicine Efforts in MCL

November 7th 2019

Jia Ruan, MD, PhD, hematologist/oncologist, Weil Cornell Medicine, examined the evolving treatment landscape for mantle cell lymphoma, with an emphasis on BTK inhibitors.

Dr. Wang on Addition of Acalabrutinib to Bendamustine/Rituximab in MCL

November 2nd 2019

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the addition of acalabrutinib (Calquence) to bendamustine and rituximab (Rituxan; BR) in mantle cell lymphoma (MCL).

Dr. Zelenetz on Zanubrutinib Research in MCL

October 18th 2019

Andrew D. Zelenetz, MD, PhD, discusses research with zanubrutinib in mantle cell lymphoma.

Dr. Gerson on Strategies Aimed at Alleviating Toxicity in Older Patients With MCL

October 15th 2019

James N. Gerson, MD, assistant professor of clinical medicine, Perelman School of Medicine, University of Pennsylvania, discusses strategies aimed at alleviating toxicity in older patients with mantle cell lymphoma (MCL).